



Comparative analysis between radioactive seed localization and wire-guided for non-palpable breast cancer surgery

Ferreira^a H.J., Zeituni^a C.A., Rigo^a M. E. Z., Santos^a H.N., Rosero^a W. A. A.,
Alcantara^a G. F., Rostelato^a M. E. C. M.

^a Energy and Nuclear Research Institute/ Radiation Technology Center, 05508-000, São Paulo, São Paulo, Brazil.
hortenciaferreira.radiologia@gmail.com

ABSTRACT

The conservative surgery for impalpable breast cancer requires an intraoperative localization method that guides the identification and correct excision of the lesion. The aim of this study is to comparatively analyze two intraoperative breast localization technologies, wire guided localization (WGL) and radioactive seed localization (RSL), regarding their surgical efficacy through the outcomes of surgical margins, intraoperative re-excision, reoperation and recurrence. To this end, a systematic search was realized in databases for clinical trials that match with the study eligibility criteria. The selected studies were evaluated for their methodological quality; the data were then collected and quantitatively synthesized. The results comprised thirty-eight studies that match the eligibility criteria. The main outcomes reported demonstrating that the RSL is at least equivalent to the WGL in efficiency rates. These results confirm the method applicability for impalpable breast lesions surgery in an effective way, in addition to presenting organizational optimization of radiology and surgery services by allowing the surgery to be performed up to two months after seed implantation.

Keywords: breast conserving surgery, radioactive seed localization, wire guided localization.



1. INTRODUCTION

Breast cancer is the most common women malignant neoplasm in Brazil [1]. Currently, as a result of the Health Ministry mammographic screening program, about a third of diagnosed breast cancers are in early stages [2], which makes it possible to carry out breast-conserving surgery, which is the removal of only the tumor. Lesions in early stages that yet are impalpable require an intraoperative marking method to help the surgeon to locate the lesion accurately, contributing to an adequate resection with negative surgical margins.

The most widely adopted approach for intraoperative marking of non-palpable breast tumors is wire-guided localization (WGL) [3,4]. The method consists of introducing the metallic wire into the area of the lesion, under mammography or ultrasound guidance. After positioning, the wire projects out of the breast, which requires care such as dressings and immobilization, to prevent wire breakage and displacement. Thus, the appointment and surgery must be performed on the same day.

One radio-guided option for labeling is localization with 125-iodine seed, first described in 1999 by Dauway [5]. In this technique, the radioactive seed is inserted into the breast, under mammography or ultrasound guidance, marking the site of the lesion, which is excised in the surgical procedure with continuous and audible assistance from a gamma detector. The greatest benefit of RSL highlighted in the literature [3,4] is the flexibility of surgical planning, because the seed can be introduced into the breast up to 2 months before surgery, due to the physical half-life of iodine-125, which is 59.4 days, improving the technical and organizational logistics for radiology and surgery teams.

Though being a new technique, RSL has the logistical benefit of making appointments in the radiology and surgery sectors more flexible, in addition to being a less invasive procedure for the patient. The aim of this study is to investigate the surgery efficiency of radioactive seed localization compared to metallic wire localization, evaluating the outcomes of positive surgical margins, intraoperative re-excision, reoperation and recurrence, with the view to indicate the incorporation of RSL technology for nonpalpable breast cancer surgical localization.

2. MATERIALS AND METHODS

The systematically research was performed in ClinialTrials.gov, Cochrane library, CRD database, EMBASE, HTA database, LILACS, PubMed, SciELO, Trip database and Web of Science from the earliest available data to August 2, 2021. The search strategy used, made in PubMed and adapted for the other databases, was: ((((((breast cancer[MeSH Terms]) OR (breast surgery[MeSH Terms])) OR (((breast cancer*) OR (breast neoplasm*)) OR (breast carcinoma*)) OR (breast lesion*))) OR (((("nonpalpable") OR ("non palpable")) OR ("non-palpable")) OR ("impalpable")) OR ("occult"))) OR (((breast surgery) OR (radioguided surgery)) OR (lumpectomy*)) AND (((radioactive seed[MeSH Terms]) OR (((((((seed* localization*) OR (radioactive seed*)) OR (radioguided seed*)) OR (iodine seed*)) OR (iodine-125)) OR (125I seed*)) OR (rollis)) OR (rsl))) OR (((wire localization) OR (wgl)) OR (radioguided occult lesion localization)) OR (roll))).


The identified studies through the search strategy were selected after reading the title and abstract, when this was inconclusive, the article was analyzed in full text for inclusion. Data were extracted using a standardized form that collected study information (authors, title, publication year, country, design), population characteristics (participants number, age, clinical and pathological information about the lesion), methodology (assessed interventions, procedure description, assessed outcomes) and results by outcome.

The selected studies were evaluated for risk of bias, using their specific tool for each design. In addition, for all studies, the presence of conflicts of interest was analyzed. Randomized clinical trials were evaluated according to the ROB 2 tool [6], on the domains of random generation and allocation; blinding of participants, professionals and outcome evaluators; incomplete outcomes and selective outcome reporting. Observational studies, in turn, were evaluated according to the ROBINS I tool [7], on the domains of confusion; study participants selection; interventions classification; deviations from the intended interventions; data missing; results measurement and the reported result selection. The results of the risk of bias assessment were illustrated in graphs, using the robvis tool [8]. Then, after collection and analysis, the results were compiled according to the outcome measured.

3. RESULTS AND DISCUSSION

Through database searches, we retrieved 5204 records, of which 4913 were excluded after screening by title and abstract. Finally, we excluded a further 253 articles in the full text screening, because that were: abstracts or posters (n=80), bibliographic reviews (n=36), author comments (n=6), secondary studies (n=14), clinical trials with no published result (n=3), case series without a comparator (n= 28), did not meet any of the eligibility criteria (n=69) and full text was not found in 17 cases. Therefore, 38 articles were included. See figure 1, which shows the study selection flowchart.

Figure 1: Flowcart of study selection.



Source: by the authors, adapted from PRISMA [9]

The evidence overall quality was good for randomized trials and moderate for cohort studies. The main bias risk among the randomized trials consisted of incomplete outcomes, data missing about selective outcome reporting, randomized allocation sequence and allocation sequence concealment. For cohort studies, the main risk of bias among consisted of baseline confusion, data missing and outcome measurement bias. See figure 2 and 3, which shows the risk of bias results assessment in randomized and non-randomized clinical studies, respectively.

Study	Risk of bias			
	D1	D2	D3	D4
Bloomquist 2016	-	+	X	-
Fung 2016	+	+	-	+
Gray 2001	-	+	X	-
Langhans 2017	+	+	-	+
Lovrics 2011	+	+	X	+
Taylor 2021	+	+	-	+

D1: Random generation and allocation
 D2: Blinding of participants, professionals and outcome evaluators
 D3: Incomplete outcomes
 D4: Selective outcome report

Judgement
 X High
 - Unclear
 + Low

Figure 2: risk of bias in randomized clinical trials.
 Source: by the authors, using the robvis tool [8]

Study	Risk of bias					
	D1	D2	D3	D4	D5	D6
Agahozo 2020	+	+	-	-	-	+
Aljohani 2018	X	+	-	-	+	+
Angarita 2019	-	+	-	+	+	+
Armau 2020	+	-	+	+	+	+
Chiu 2014	X	+	X	+	X	X
Diego 2014	X	+	-	-	+	+
Dryden 2016	-	+	-	+	+	+
Gray 2004	+	+	-	+	X	X
Horwood 2019	X	+	X	-	+	+
Hout 2016	X	+	+	+	+	+
Hughes 2008	X	+	-	+	X	X
Jumaa 2020	X	+	X	-	+	+
Law 2020	-	+	-	+	+	+
Luiten 2015	+	+	-	+	+	+
Miligan 2017	+	+	-	+	+	+
Murphy 2013	X	+	+	+	+	+
Murphy 2018	-	+	-	-	+	+
Parvez 2018	X	+	X	-	-	+
Pieri 2017	X	+	-	+	+	+
Rao 2010	X	+	-	+	+	+
Rarick 2016	+	+	-	+	+	+
Sanchez 2019	X	+	+	+	+	+
Saphier 2020	X	+	-	-	+	+
Sharek 2015	+	+	-	+	-	+
Silva 2017	-	+	X	-	+	+
Srouf 2019	X	+	+	+	+	+
Srouf 2020	X	+	+	-	+	+
Stelle 2017	X	+	-	-	+	+
Theunissen 2017	-	-	-	+	+	X
Tran 2017	+	+	-	+	+	+
Zenzola 2006	X	+	+	+	+	+
Zhang 2017	-	+	+	+	+	+

D1: Confusion bias
 D2: Selection bias
 D3: Classification bias of interventions
 D4: Deviation bias from intended interventions
 D5: Missing data
 D6: Results measurement bias

Judgement
 X High
 - Moderate
 + Low

Figure 3: risk of bias in non randomized studies. Source: by the authors, using the robvis tool [8]

The 38 [10-47] studies that met the inclusion criteria was 6 randomized controlled trials and 32 cohort studies. The population includes women with non-palpable invasive or ductal in situ breast cancer, aged 22-92 years, and includes patients who underwent neoadjuvant chemotherapy and bracketing localization. 32 studies reported the outcome of positive margin, 14 reported intraoperative re-excision, 27 reported reoperation and 3 reported recurrence.

The positive margin results, with a population of 6835 women in the RSL group and 8266 in the WGL group, was 15.8% and 17.3%, respectively. A total of 33.6% of 2437 women in the RSL group and 42.7% of 2671 in the WGL group required intraoperative re-excision. 12.6% of 6152 women in the RSL group and 15.7% of 7732 in the WGL group underwent reoperation. 527 patients in the RSL group and 998 in the WGL group were followed up for a period of 13-109 months, disease recurrence occurred - recurrence local, regional or distant metastasis - in 1.5% of the cases of RSL and 3, 6% WGL.

The conservative surgery success depends on the tumor complete removal, achieved with negative surgical margins. The positive margins occurrence is related to the disease recurrence risk, which, to be limited, needs reoperation. Overall, this study included a large group of patients receiving conservative surgery with either RSL or WGL, using real-world multicenter data about women with DCIS and IC, including neoadjuvant chemotherapy and bracketing localization cases. The RSL results for the analyzed outcomes was slightly better compared to WGL, implying that RSL is at least equivalent to WGL in terms of efficiency in intraoperative localization.

Once the seeds insertion can take place up to 2 months before the surgery, there is a logistical improvement for the radiology and surgery sector. The radiologist can see several cases a day to perform seed marking and patients do not need to go to the radiology department on the day of surgery. Thus, conservative surgeries with RSL can be the first surgical case of the day, improving the use of the operating room.

Patients underwent neoadjuvant chemotherapy can receive RSL implant prior to neoadjuvant treatment and thus will not need to undergo another localization procedure prior to surgery. This is especially important for patients who achieve a complete pathological response, as the seed will continue to mark the tumor local even with tumor regression [48].

The RSL technique implementation, due to its radioactive nature, requires the regulatory procedures establishment involving radiology, surgery and pathology departments. However, when the institution has a nuclear medicine department, the necessary personnel and equipment will be the same, what provide one sustainable implementation [49].

To support one localization technique over the other, the interventions estimated effect should be analyzed through a meta-analysis for provide the results magnitude within the scope of these findings; In addition, evidence treating about safety and services organization is needed, comprising aspects of patient assessment of pain, cosmesis and satisfaction related to the procedure; technique evaluation by the medical team; marker-related and postoperative complications; localization time; operative time; time interval between localization and surgery; and in addition, cost information.

4. CONCLUSION

The result of this study provides evidence that for patients with non-palpable breast cancer, RSL is a valid localization method, with efficiency equivalent to WGL. Can be applied in various indications for breast-conserving surgery with intraoperative localization, from patients who receive a single marker, to bracketing localization cases and associated neoadjuvant treatment. In addition, RSL providing improvement the logistical organization of the radiology and surgery departments.

REFERENCES

- [1] Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). **ABC do câncer: abordagens básicas para o controle do cancer**. 6. ed. Rio de Janeiro, Brasil (2020).
- [2] Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). **A situação do câncer de mama no Brasil: síntese de dados dos sistemas de informação**. Rio de Janeiro, Brasil (2019).
- [3] Chan B. K. Y.; Wiseberg-Firtell J. A.; Jois R. H. S.; et al. Localization techniques for guided surgical excision of non-palpable breast lesions. **Cochrane Database of Systematic Reviews**, (2015).

- [4] Moreira I. C.; Ventura S. R.; Ramos I.; et al. Preoperative localisation techniques in breast conservative surgery: A systematic review and meta-analysis. **Surgical Oncology**, vol. 35, pp. 351-373 (2020).
- [5] Dauway E. Innovative Diagnostics for Breast Cancer: New Frontiers for the New Millennium Using Radioactive Seed Localization, In : Surgical Forum: **85th Annual American College of Surgeons Clinic Congress**, Chicago, vol. 50 (1999).
- [6] Higgins J. P. T.; Sterne J. A. C.; Savović J.; et al. A revised tool for assessing risk of bias in randomized trials. *Cochrane Methods*. **Cochrane Database of Systematic Reviews** 2016, Issue 10 (Suppl 1). dx.doi.org/10.1002/14651858.CD201601.
- [7] Sterne J. A.; Hernán M. A.; Reeves B. C.; et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. **BMJ** 2016; 355 :i4919 doi:10.1136/bmj.i4919.
- [8] McGuinness L.A.; Higgins J.P.T. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. **Res Syn Meth.** 2020; 1- 7. <https://doi.org/10.1002/jrsm.1411>
- [9] Page M. J.; McKenzie J. E.; et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. **BMJ** 2021;372:n71. Doi: 10.1136/bmj.n71.
- [10] Bloomquist E. V ; Ajkay N.; Patil S.; et al. A Randomized Prospective Comparison of Patient-Assessed Satisfaction and Clinical Outcomes with Radioactive Seed Localization versus Wire Localization. **The Breast Journal**, Volume 22 Number 2, 2016 151–157 . DOI: 10.1111/tbj.12564.
- [11] Fung F.; Cornacchi S. D.; Reedijk M.; et al. Breast cancer recurrence following radioguided seed localization and standard wire localization of nonpalpable invasive and in situ breast cancers: 5-Year follow-up from a randomized controlled Trial. **The American Journal of Surgery** xxx (2016) 1e7. Doi: 10.1016/j.amjsurg.2016.06.016.
- [12] Gray R. J.; Salud C.; Nguyen K.; et al. Randomized Prospective Evaluation of a Novel Technique for Biopsy or Lumpectomy of Nonpalpable Breast Lesions: Radioactive Seed Versus Wire Localization. **Annals of Surgical Oncology**, 8(9):711–715.
- [13] Langhans L.; Tvedskov T. F.; Klausen T. L.; et al. Radioactive Seed Localization or Wire-guided Localization of Nonpalpable Invasive and In Situ Breast Cancer. **Annals of Surgery**, Volume 266, Number 1, July 2017.

- [14] Lovrics P. J.; Goldsmith C. H.; Hodgson N.; et al. A Multicentered, Randomized, Controlled Trial Comparing Radioguided Seed Localization to Standard Wire Localization for Nonpalpable, Invasive and in situ Breast Carcinomas. **Ann Surg Oncol** (2011) 18:3407–3414. DOI 10.1245/s10434-011-1699-y.
- [15] Taylor D. B.; Bourke A. G.; Westcott E. J.; et al. Surgical outcomes after radioactive 125I seed versus hookwire localization of non-palpable breast cancer: a multicentre randomized clinical Trial. **BJS**, 2021, 108, 40–48. DOI: 10.1093/bjs/znaa008.
- [16] Agahoso M. C.; Berghuis S. A. M.; van den Broek E.; et al. Radioactive Seed Versus Wire-Guided Localization for Ductal Carcinoma in Situ of the Breast: Comparable Resection Margins. **Ann Surg Oncol**. Doi: 10.1245/s10434-020-08744-8.
- [17] Aljohani B.; Jumaa K.; Kornecki A.; et al. Clinical utility of radioactive seed localization in nonpalpable breast cancer: A Retrospective single institutional cohort study. **International Journal of Surgery**. Doi:10.1016/j.ijssu.2018.11.004.
- [18] Angarita F. A.; Acuna S. A.; Down N.; et al. Comparison of Radioactive Seed Localized Excision and Wire Localized Excision of Breast Lesions: A Community Hospital’s Experience. **Clinical Breast Cancer**. 1526-8209. Doi: 10.1016/j.clbc.2019.01.001.
- [19] Arnau I. M.; Sanchez R. S.; Casas M. C.; et al. Surgical clips vs. iodine-125 (125I) seeds for marking the location of nonpalpable malignant breast lesions: preliminary results. **Radiología**. 2020;62(1):38-45.
- [20] Chiu J. C.; Ajmal S.; Zhu X.; et al. Radioactive Seed Localization of Nonpalpable Breast Lesions in an Academic Comprehensive Cancer Program Community Hospital Setting. **The american surgeon**. July 2014 Vol. 80.
- [21] Diego E. J.; Soran A.; McGuire K. P.; et al. Localizing High-Risk Lesions for Excisional Breast Biopsy: A Comparison Between Radioactive Seed Localization and Wire Localization. **Ann Surg Oncol** (2014) 21:3268–3272. DOI: 10.1245/s10434-014-3912-2.
- [22] Dryden M. J.; Dogan B. E.; Fox P.; et al. Imaging Factors That Influence Surgical Margins After Preoperative 125I Radioactive Seed Localization of Breast Lesions: Comparison With Wire Localization. **AJR** 2016; 206:1112–1118.

- [23] Gray R. J.; Pockaj B. A.; Karstaedt P. J.; et al. Radioactive seed localization of nonpalpable breast lesions is better than wire localization. **The American Journal of Surgery** 188 (2004) 377–380.
- [24] Horwood C. R.; Grignol V.; Lahey S.; et al. Radioactive seed vs wire localization for nonpalpable breast lesions: A single institution review. **Breast J.** 2019;1–4. DOI: 10.1111/tbj.13201.
- [25] Hout B. A.; Schenk K. E. van der Linden A. N.; et al. Efficacy of localization of non-palpable, invasive breast cancer: Wire localization vs. Iodine-125 seed: A historical comparison. **The Breast** 29 (2016) 8e13. Doi: 10.1016/j.breast.2016.06.011.
- [26] Hughes J. H.; Mason M. C.; Gray R. J.; et al. A Multi-site Validation Trial of Radioactive Seed Localization as an Alternative to Wire Localization. **The Breast Journal**, Volume 14 Number 2, 2008 153–157.
- [27] Jumaa K.; Aljohani B.; Brackstone M.; et al. A Single-Institute Experience With Radioactive Seed Localization of Breast Lesions—A Retrospective Study. **Canadian Association of Radiologists Journal** 2020, Vol. 71(1) 58-62. DOI: 10.1177/0846537119885682.
- [28] Law W.; Cao X.; Wright F. C.; et al. Adequacy of invasive and in situ breast carcinoma margins in radioactive seed and wire-guided localization lumpectomies. **Breast J.** 2020;00:1–7. DOI: 10.1111/tbj.14115.
- [29] Luiten J. D.; Beek M. A.; Voogd A. C.; et al. Iodine seed- versus wire-guided localization in breast-conserving surgery for non-palpable ductal carcinoma *in situ*. **BJS** 2015; 102: 1665–166.
- [30] Miligan R.; Pieri A.; Critchley A.; et al. Radioactive seed localization compared with wireguided localization of non-palpable breast carcinoma in breast conservation surgery— the first experience in the United Kingdom. **BJ Radiol** 2018; 91: 20170268.
- [31] Murphy J. O.; Moo T.; King T. A.; Radioactive Seed Localization Compared to Wire Localization in Breast-Conserving Surgery: Initial 6-Month Experience. **Ann Surg Oncol** (2013) 20:4121–4127. DOI 10.1245/s10434-013-3166-4.
- [32] Murphy B. L.; Boughey J. C.; Keeney M. G.; et al. Factors Associated With Positive Margins in Women Undergoing Breast Conservation Surgery. **Mayo Clin Proc.** n XXX 2017;nn(n):1-7 n. Doi10.1016/j.mayocp.2017.11.023

- [33] Parvez E.; Cornachi S. D.; Fu E.; et al. Adoption and outcomes of radioguided seed localization for nonpalpable invasive and in-situ breast cancer at three academic tertiary care centers. **The American Journal of Surgery** xxx (2018) 1e6. Doi: 10.1016/j.amjsurg.2018.07.007.
- [34] Pieri A.; Milligan R.; Critchley A.; et al. The introduction of radioactive seed localisation improves the oncological outcome of image guided breast conservation surgery. **The Breast** 36 (2017) 49e53. Doi:10.1016/j.breast.2017.09.004.
- [35] Rao R.; Moldrem A.; Sarode V.; et al. Experience with Seed Localization for Nonpalpable Breast Lesions in a Public Health Care System. **Ann Surg Oncol** (2010) 17:3241–3246. DOI: 10.1245/s10434-010-1139-4.
- [36] Rarick J.; Kimler B. F.; Tawmfik O. Comparison of margin status and lesional size between radioactive seed localized vs conventional wire localized breast lumpectomy specimens. **Annals of Diagnostic Pathology** 21 (2016) 47–52.
- [37] Sanchez R. S.; Jiménez A. D. G.; Aguirre A. C. R.; et al. 125I radioactive seed localization for non-palpable lesions in breast cancer. **Rev Esp Med Nucl Imagen Mol.** 2019;xxx(xx):xxx–xxx.
- [38] Saphier N.; Kondraciuk J.; Morris E.; et al. Preoperative Localization of Breast MRI Lesions: MRI-guided Marker Placement With Radioactive Seed Localization as an Alternative to MRI-guided Wire Localization. **Journal of Breast Imaging**, 2020, Vol. 2, Issue 3, 250–258. Doi:10.1093/jbi/wbaa012.
- [39] Sharek D.; Zuley M. L.; Zhang J. Y.; et al. Radioactive seed localization versus wire localization for lumpectomies: a comparison of outcomes. **AJR** 2015; 204:872–877. DOI:10.2214/AJR.14.12743.
- [40] Silva M.; Porembka J.; Mokdad A. A.; et al. Bracketed radioactive seed localization vs bracketed wire-localization in breast surgery. **Breast J.** 2017;1–6. DOI: 10.1111/tbj.12854.
- [41] Srour M. K.; Kim S.; Amersi F.; et al. Comparison of wire localization, radioactive seed, and Savi scout radar for management of surgical breast disease. **Breast J.** 2019;00:1–8. DOI: 10.1111/tbj.13499.

- [42] Srour M. K.; Kim S.; Amersi F.; et al. Comparison of Multiple Wire, Radioactive Seed, and Savi Scout_ Radar Localizations for Management of Surgical Breast Disease. **Ann Surg Oncol**. Doi: 10.1245/s10434-020-09159-1.
- [43] Stelle L.; Schoenheit T.; Brubaker A.; et al. Radioactive Seed Localization Versus Wire Localization for Nonpalpable Breast Lesions: A Two-Year Initial Experience at a Large Community Hospital. **Ann Surg Oncol**. Doi: 10.1245/s10434-017-6102-1.
- [44] Theunissen C. I. J. M.; Rust E. A. Z.; Edens M. A.; et al. Radioactive seed localization is the preferred technique in nonpalpable breast cancer compared with wire-guided localization and radioguided occult lesion localization. **Nuclear medicine communications**. DOI: 10.1097/MNM.0000000000000659.
- [45] Tran V. T.; David J.; Patocskai E.; et al. Comparative Evaluation of Iodine-125 Radioactive Seed Localization and Wire Localization for Resection of Breast Lesions. **Canadian Association of Radiologists Journal** xx (2017) 1e9. Doi:10.1016/j.carj.2017.04.006
- [46] Zenzola V.; Hidalgo F.; Paredes R.; et al. Estudio comparativo entre radiolocalización con aguja arpón y uso de semillas radioactivas de yodo125 en lesiones subclínicas de mama. **Rev Venez Oncol** 2006;18(3):136-143.
- [47] Zhang Y.; Seely J.; Cordeiro E.; et al. Radioactive Seed Localization Versus Wire-Guided Localization for Nonpalpable Breast Cancer: A Cost and Operating Room Efficiency Analysis. **Ann Surg Oncol** DOI: 10.1245/s10434-017-6084-z.
- [48] Gobardhan P. D.; Wall L. L.; van der Laan L.; et al. The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy. **Annals of Oncology**, vol. 24, pp. 668-673 (2013).
- [49] Institute national d'excellence em santé et em services sociaux (INESSS). **Utilisation de la bille radioactive pour la localisation préopératoire de tumeurs mammaires non palpables**. Québec, Qc: INESSS (2015).